Sage Journals: Discover world-class research

Abstract

Background:

Despite the increased use of percutaneous interventions, infarction-related cardiogenic shock (CS) is still associated with high mortality. Biomarkers might be helpful to identify patients at risk, and point towards novel therapeutic strategies in CS. The phosphaturic hormone fibroblast growth factor 23 (FGF-23) has recently been introduced as a predictor for mortality in patients with chronic systolic heart failure. However, its predictive role in CS has not been investigated so far.

Methods and results:

FGF-23 was measured in 51 patients with CS. Eighteen patients with uncomplicated acute myocardial infarction (AMI) and 940 patients with stable coronary artery disease (CAD) undergoing elective coronary angiography included in a previous study served as control groups. Compared with patients with stable CAD, FGF-23 was profoundly elevated in patients with CS, but not in patients with uncomplicated AMI (CAD: 131.1±9.5; AMI: 175.3 ±57.2; CS: 1684.4±591.7 rU/ml, p<0.0001 CS vs. CAD). In patients with CS, FGF-23 correlated significantly with the SAPS II score (r=0.461, p=0.0003) and NT-pro BNP levels (r=0.489, p=0.001). Patients were stratified as “survivors” and “non-survivors” according to their 28-day mortality. The overall 28-day-mortality-rate was 37%. Non-survivors of CS showed significantly higher FGF-23 levels compared with survivors (3260.1±1514.7 vs. 847.9±182.4 rU/ml, p=0.028). In the ROC curve analysis, FGF-23 levels predicted 28-day mortality (area under the curve (AUC) 0.686, p=0.028), and FGF-23 level of 1180 rU/ml was identified as optimal cut-off value. In a multivariate Cox proportional hazard model adjusted for gender, blood pressure, ejection fraction and levels of creatine kinase, FGF-23 levels above 1180 rU/ml significantly predicted 28-day mortality (hazard ratio (HR) 2.74, 95% CI 1.01-7.04, p=0.037).

Conclusion:

In CS, a tremendous increase in FGF-23 occurs, and high levels of FGF-23 are associated with poor outcome.

Keywords

Cardiogenic shock FGF-23 outcome predictors

Get full access to this article

View all access options for this article.

References

McMurray

Adamopoulos

Anker

. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Failure 2012; 14: 803–869.

Goldberg

Samad

Yarzebski

. Temporal trends in cardiogenic shock complicating acute myocardial infarction. New Engl J Med 1999; 340: 1162–1168.

Goldberg

Spencer

Gore

. Thirty-year trends (1975 to 2005) in the magnitude of, management of, and hospital death rates associated with cardiogenic shock in patients with acute myocardial infarction: A population-based perspective. Circulation 2009; 119: 1211–1219.

Kouraki

Schneider

Uebis

. Characteristics and clinical outcome of 458 patients with acute myocardial infarction requiring mechanical ventilation. Results of the BEAT registry of the ALKK-study group. Clin Res Cardiol 2011; 100: 235–239.

Hochman

. Cardiogenic shock complicating acute myocardial infarction: Expanding the paradigm. Circulation 2003; 107: 2998–3002.

Foley

. Phosphate Levels and Cardiovascular Disease in the General Population. Clin J Am Soc Nephro 2009; 4: 1136–1139.

Tuttle

Short

. Longitudinal Relationships among Coronary Artery Calcification, Serum Phosphorus, and Kidney Function. Clin J Am Soc Nephro 2009; 4: 1968–1973.

Larsson

Olauson

Hagstrom

. Conjoint effects of serum calcium and phosphate on risk of total, cardiovascular, and noncardiovascular mortality in the community. Arterioscler Thromb Vasc Biol 2010; 30: 333–339.

Tonelli

Curhan

Pfeffer

. Relation between alkaline phosphatase, serum phosphate, and all-cause or cardiovascular mortality. Circulation 2009; 120: 1784–1792.

10.

Riminucci

Collins

Fedarko

. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 2003; 112: 683–692.

11.

Larsson

. The role of FGF-23 in CKD-MBD and cardiovascular disease: friend or foe? Nephrol Dialysis Trans 2010; 25: 1376–1381.

12.

Heine

Seiler

Fliser

. FGF-23: the rise of a novel cardiovascular risk marker in CKD. Nephrol Dialysis Trans 2012; 27: 3072–3081.

13.

Kendrick

Cheung

Kaufman

. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 2011; 22: 1913–1922.

14.

Isakova

Xie

Yang

. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011; 305: 2432–2439.

15.

Seiler

Reichart

Roth

. FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol Dialysis Trans 2010; 25: 3983–3989.

16.

Parker

Schurgers

Brandenburg

. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: The Heart and Soul Study. Ann Int Med 2010; 152: 640–648.

17.

Katz

Kestenbaum

. Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). J Am Coll Cardiol 2012; 60: 200–207.

18.

Faul

Amaral

Oskouei

. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121: 4393–4408.

19.

Gutierrez

Januzzi

Isakova

. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009; 119: 2545–2552.

20.

Mirza

Larsson

Melhus

. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 2009; 207: 546–551.

21.

Seiler

Cremers

Rebling

. The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation. Eur Heart J 2011; 32: 2688–2696.

22.

Gruson

Lepoutre

Ketelslegers

. C-terminal FGF23 is a strong predictor of survival in systolic heart failure. Peptides 2012; 37: 258–262.

23.

Plischke

Neuhold

Adlbrecht

. Inorganic phosphate and FGF-23 predict outcome in stable systolic heart failure. Eur J Clin Invest 2012; 42: 649–656.

24.

The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI Study Group. New Engl J Med 1985; 312: 932–936.

25.

Hochman

Sleeper

Webb

. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. New Engl J Med 1999; 341: 625–634.

26.

Idanpaan-Heikkila

. WHO guidelines for good clinical practice (GCP) for trials on pharmaceutical products: responsibilities of the investigator. Ann Med 1994; 26: 89–94.

27.

Le Gall

Lemeshow

Saulnier

. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993; 270: 2957–2963.

28.

Thygesen

Alpert

Jaffe

. Third universal definition of myocardial infarction. Eur Heart J 2012; 33: 2551–2567.

29.

Link

Pöss

Rbah

. Circulating angiopoietins and cardiovascular mortality in cardiogenic shock. Eur Heart J 2013 Jan 24. [Epub ahead of print].

30.

Werdan

Russ

Buerke

. Cardiogenic shock due to myocardial infarction: diagnosis, monitoring and treatment: a German-Austrian S3 Guideline. Deutsches Arzteblatt Int 2012; 109: 343–351.

31.

Seiler

Wen

Roth

. Plasma Klotho is not related to kidney function and does not predict adverse outcome in patients with chronic kidney disease. Kidney Int 2013; 83: 121–128.

32.

Gutierrez

Mannstadt

Isakova

. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. New Engl J Med 2008; 359: 584–592.

33.

Heine

Nangaku

Fliser

. Calcium and phosphate impact cardiovascular risk. Eur Heart J 2013; 34: 1112–21

34.

Bhattacharyya

Chong

Gafni

Collins

. Fibroblast growth factor 23: State of the field and future directions. Trends Endocrinol Metab 2012; 23: 610–8.

35.

de Borst

Vervloet

ter Wee

Navis

. Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease. J Am Soc Nephrol 2011; 22: 1603–1609.

FGF-23 is associated with increased disease severity and early mortality in cardiogenic shock

Abstract

Background:

Methods and results:

Conclusion:

Keywords

Get full access to this article

References